Cognition Therapeutics Inc CGTX rose 12.10% to $0.45 during after hours on Thursday, following a surge of 20.82% gain during regular hours.
What Happened: The hike in Cognition Therapeutics’ stock price is attributed to the promising results from its Alzheimer’s drug, Zervimesine. The drug achieved a 95% efficacy rate in its Phase 2 trial. The trial also reached a 50% enrollment milestone, further boosting investor confidence in the drug’s potential.
See Also: Bitcoin, Ethereum, Dogecoin Surge Amid Trump’s ‘One Big, Beautiful Bill’ Victory — Analyst Says BTC On ‘Cusp Of Making History’ As It Eyes Key Weekly Resistance – Grayscale Bitcoin Mini Trust (BTC)
Why It Matters: The Alzheimer’s drug market has been a hotbed of activity recently. InMed Pharmaceuticals Inc. INM , for instance, experienced a sudden surge in its stock price after releasing new preclinical data demonstrating the potential of its therapeutic candidate for Alzheimer’s disease.
Price in Action: According to Benzinga Pro data, Cognition Therapeutics' stock rose 20.82% to $0.41 during regular trading, followed by an additional 12.10% gain to $0.45 in after-hours trading.
Benzinga's Edge Stock Rankings indicates Cognition Therapeutics has momentum in the 3rd percentile. For the complete picture on the stock, click here .
Loading... Loading...Read Next:
Trump Says Elon Musk Would ‘Close Up Shop And Head Back Home To South Africa’ Without Subsidies: ‘No More Rocket Launches, Satellites, Or Electric Car’Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: Martin Gregor on Shutterstock.com
CGTX Cognition Therapeutics Inc $0.4540 35.4%Stock Score Locked: Edge Members Only
Benzinga Rankings give you vital metrics on any stock – anytime.
Unlock RankingsEdge Rankings
Momentum 3.95Price Trend
Short Medium Long Overview INM InMed Pharmaceuticals Inc $2.89 -5.25% Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Biotech Equities News Health Care Market-Moving Exclusives Markets Alzheimers benzinga neuro Cognition Therapeutics Inc healthcare InMed Pharmaceuticals Inc. pharmaceuticals why it's moving Zervimesine